Partnership combines Tennr's patient orchestration technology with ACU-Serve's revenue cycle expertise to help providers scale, improve intake efficiency and move patients to care faster.
Read More
Bridging ancient Amazonian botanicals with modern mindfulness practices, Sacred Connection offers a fast-acting grounding tool to quiet internal noise before meditation sits.
Read MoreCompany remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027
Read More
Offering a natural, plant-based alternative to chemical decongestants and pain relievers, Sacred Connection brings direct-trade botanical preparations to those seeking rapid head and sinus relief.
Read More
Combining radical supply-chain transparency with direct non-profit action, Sacred Connection funds clean water infrastructure, cultural preservation, and land stewardship across Huni Kuin, Yawanawá, and Katukina villages.
Read More● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16
● Presentation covers Phase 1a first-in-human results for Conjugated Psilocin™ (L-130), including oral bioavailability, dose consistency and the absence of hallucinogenic effects at low doses
● Lobe to exhibit throughout the summit, September 15-17, alongside senior discovery, clinical and business development leaders from major pharmaceutical companies
Read MoreAdvances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026
Expands European commercialization readiness, including surgeon training and regulatory approval of new manufacturing process that improves production yield 400%
Strengthened balance sheet with $6.5 million private placement in June 2026
Read More
This private, veteran-only retreat will offer medically supervised plant medicine treatment and long-term integration support for veterans living with treatment-resistant PTSD
Read More
Bridging ancestral Amazonian wisdom with modern somatic wellness, Sacred Connection introduces ethically sourced Hapé blends designed to reset overstimulated minds in 60 seconds.
Read More
The physician-led longevity and regenerative medicine practice is opening its first clinic in the Orlando area and is now accepting patients for the waitlist ahead of its September 28 opening.
Read MoreContinuation of treatment with blinded doses of crofelemer in the extension phase of the trial will support company's plans to file an NDA in mid-2027 for MVID, an ultrarare pediatric disease
Read More
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs
Jaguar expects Neonorm Dog to be available through other select online and animal health retail channels shortly, including Chewy
Read MoreAs millions of Americans spend the holiday caring for aging parents and loved ones, Guardian Angel AI is building technology designed to make aging at home safer - and caregiving less consuming.
Read MoreJaguar remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to parenteral support (PS) for pediatric and adult rare IF diseases, including microvillus inclusion disease (MVID)
Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval
Read MoreBundled Valenz solutions for surgeries, imaging, specialty infusions, and catastrophic care now fully integrated into HealthJoy's Benefits Operating System to drive additional 50%+ savings
Read MoreDr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience
Current CFO, Mirza Rahimani, transitions to Vice President of Finance, providing continuity across financial reporting and operations
Appointment strengthens Lobe's leadership team as the Company advances L-130, its differentiated conjugated psilocin therapeutic being developed at sub-hallucinogenic doses for chronic cluster headache
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance in dogs
Jaguar expects to make Neonorm Dog available through both Amazon and Chewy soon
Read MoreCompany remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID); company expects clinical package for NDA for MVID to be ready by end of 2026, allowing submission of NDA in Q2 2027
REMINDER: Jaguar to host investor webcast Wednesday, August 19 at 4:30 p.m. Eastern regarding Q2 2026 financials and company updates (click here to register)
Read More
Integration with Proscia's Concentriq platform will facilitate pharma companies, diagnostic assay and platform providers, and CROs in operationalizing companion diagnostic programs
Read More
Introducing Magnesium L-Theanine Complex™ for relaxation and restorative sleep, and TreBiome™, a full-spectrum pre-, pro-, and postbiotic supporting total microbiome balance and both gut and vaginal health.
Read More
The additional capacity at the Austin, Texas, center responds to sustained demand for adolescent residential mental health care, with the new beds expected to be available in August 2026.
Read MoreAs announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure (IF) indications
Presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID)
Read More